SoftOx Solutions AS (“SoftOx”) is pleased to announce that it has formally submitted a clinical trial application (CTA) to the Danish Medicines Agency for approval of its upcoming dose-escalation / Phase 2a clinical study in people with cystic fibrosis (CF). This submission marks a significant milestone in SoftOx’s clinical development strategy and is the decisive step toward initiating human ef...